Schizophrenia and comorbid substance use disorder: Effects of antipsychotics

Journal of Clinical Psychiatry

Volumn 66, Issue SUPPL. 6, 2005, Pages 21-26

  Green, Alan I ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ATYPICAL ANTIPSYCHOTIC AGENT; CANNABIS; CLOZAPINE; COCAINE; NEUROLEPTIC AGENT; NICOTINE; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ADDICTION; ALCOHOLISM; CLINICAL TRIAL; COCAINE DEPENDENCE; COMORBIDITY; DRUG EFFICACY; HEALTH CARE COST; HOSPITALIZATION; HUMAN; NEUROBIOLOGY; ONSET AGE; PATIENT COMPLIANCE; PREVALENCE; PRIORITY JOURNAL; RELAPSE; REVIEW; SCHIZOPHRENIA; SUICIDE; VIOLENCE;

ANTIPSYCHOTIC AGENTS; COMORBIDITY; DIAGNOSIS, DUAL (PSYCHIATRY); HUMANS; PREVALENCE; SCHIZOPHRENIA; SUBSTANCE-RELATED DISORDERS;

EID: 24144434939     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. Woo T-UW, Zimmet SV, Wojcik JD, et al. Treatment of schizophrenia. In: Schatzberg AF, Nemeroff CB, eds. Textbook of Psychopharmacology. 3rd ed. Washington, DC: American Psychiatric Publishing; 2004:885-912
2. Lieberman JA, Perkins D, Belger A, et al. The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches. Biol Psychiatry 2001;50:884-897
3. Lencz T, Smith CW, Auther AM, et al. The assessment of "prodromal schizophrenia": unresolved issues and future directions. Schizophr Bull 2003;29:717-728
4. McGorry PD, Yung AR, Phillips LJ, et al. Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch Gen Psychiatry 2002;59:921-928
5. Kavanagh DJ, McGrath J, Saunders JB, et al. Substance misuse in patients with schizophrenia: epidemiology and management. Drugs 2002;62:743-755
6. Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse: results from the Epidemiologic Catchment Area (ECA) study. JAMA 1990;264:2511-2518
7. Green AI, Salomon MS, Brenner MJ, et al. Treatment of schizophrenia and comorbid substance use disorder. Curr Drug Targets CNS Neurol Disord 2002;1:129-139
8. Gupta S, Hendricks S, Kenkel AM, et al. Relapse in schizophrenia: is there a relationship to substance abuse? Schizophr Res 1996;20:153-156
9. Hambrecht M, Hafner H. Substance abuse and the onset of schizophrenia. Biol Psychiatry 1996;40:1155-1163
10. Gearon JS, Bellack AS. Sex differences in illness presentation, course, and level of functioning in substance-abusing schizophrenia patients. Schizophr Res 2000;43:65-70
11. Leung A, Chue P. Sex differences in schizophrenia: a review of the literature. Acta Psychiatr Scand Suppl 2000;401:3-38
12. Green A, Tohen M, Hamer R, et al. First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol. Schizophr Res 2004;66:125-135
13. Buhler B, Hambrecht M, Loffler W, et al. Precipitation and determination of the onset and course of schizophrenia by substance abuse: a retrospective and prospective study of 232 population-based first illness episodes. Schizophr Res 2002;54:243-251
14. Veen ND, Selten JP, van der Tweel I, et al. Cannabis use and age at onset of schizophrenia. Am J Psychiatry 2004;161:501-506
15. Tsuang MT, Simpson JC, Kronfol Z. Subtypes of drug abuse with psychosis: demographic characteristics, clinical features, and family history. Arch Gen Psychiatry 1982;39:141-147
16. Drake R, Brunette M. Complications of severe mental illness related to alcohol and drug disorders. In: Galanter M, ed. Recent Developments in Alcoholism: The Consequences of Alcoholism. New York, NY: Plenum Press; 1998:285-299
17. Green AI, Canuso CM, Brenner MJ, et al. Detection and management of comorbidity in patients with schizophrenia. Psychiatr Clin North Am 2003;26:115-139
18. Richard ML, Liskow BI, Perry PJ. Recent psychostimulant use in hospitalized schizophrenics. J Clin Psychiatry 1985;46:79-83
19. Brady K, Anton R, Ballenger JC, et al. Cocaine abuse among schizophrenic patients. Am J Psychiatry 1990;147:1164-1167
20. Owen RR, Fischer EP, Booth BM, et al. Medication noncompliance and substance abuse among patients with schizophrenia. Psychiatr Serv 1996;47:853-858
21. Bowers MB Jr, Mazure CM, Nelson JC, et al. Psychotogenic drug use and neuroleptic response. Schizophr Bull 1990;16:81-85
22. Swanson JW, Holzer CE III, Ganju VK, et al. Violence and psychiatric disorder in the community: evidence from the Epidemiologic Catchment Area surveys. Hosp Community Psychiatry 1990;41:761-770
23. Bartels SJ, Teague GB, Drake RE, et al. Substance abuse in schizophrenia: service utilization and costs. J Nerv Ment Dis 1993;181:227-232
24. Dickey B, Azeni H. Persons with dual diagnoses of substance abuse and major mental illness: their excess costs of psychiatric care. Am J Public Health 1996;86:973-977
25. Khantzian EJ. The self-medication hypothesis of addictive disorders: a reconsideration and recent applications. Harv Rev Psychiatry 1997;4: 231-244
26. Green AI, Zimmet SV, Strous RD, et al. Clozapine for comorbid substance use disorder and schizophrenia: do patients with schizophrenia have a reward-deficiency syndrome that can be ameliorated by clozapine? Harv Rev Psychiatry 1999;6:287-296
27. Chambers RA, Krystal JH, Self DW. A neurobiological basis for substance abuse comorbidity in schizophrenia. Biol Psychiatry 2001;50:71-83
28. Siris SG. Pharmacological treatment of substance-abusing schizophrenic patients. Schizophr Bull 1990;16:111-122
29. McEvoy JP, Freudenreich O, Levin ED, et al. Haloperidol increases smoking in patients with schizophrenia. Psychopharmacology (Berl) 1995;119: 124-126
30. Csernansky JG, Mahmoud R, Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 2002;346:16-22
31. Collaborative Working Group on Clinical Trial Evaluations. Treatment of special populations with the atypical antipsychotics. Can J Psychiatry 1998;59:46-52
32. Hagger C, Buckley P, Kenny JT, et al. Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biol Psychiatry 1993;34:702-712
33. Meltzer HY, Alphs L, Green AI, et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry 2003;60:82-91
34. Keck PE Jr, Strakowski SM, McElroy SL. The efficacy of atypical antipsychotics in the treatment of depressive symptoms, hostility, and suicidality in patients with schizophrenia. J Clin Psychiatry 2000;61 (suppl 3):4-9
35. Drake RE, Xie H, McHugo GJ, et al. The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia. Schizophr Bull 2000;26:441-449
36. Noordsy DL, Green AI. Pharmacotherapy for schizophrenia and co-occurring substance use disorders. Curr Psychiatry Rep 2003;5:340-346
37. Varvel SA, Vann RE, Wise LE, et al. Effects of antipsychotic drugs on operant responding after acute and repeated administration. Psychopharmacology (Berl) 2002;160:182-191
38. Grace AA. Phasic versus tonic dopamine release and the modulation of dopamine system responsively: a hypothesis for the etiology of schizophrenia. Neuroscience 1991;41:1-24
39. Kapur S, Zipursky RB, Remington G, et al. 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. Am J Psychiatry 1998;155:921-928
40. Albanese MJ, Khantzian EJ, Murphy SL, et al. Decreased substance use in chronically psychotic patients treated with clozapine [letter]. Am J Psychiatry 1994;151:780-781
41. Green AI, Burgess ES, Dawson R, et al. Alcohol and cannabis use in schizophrenia: effects of clozapine vs risperidone. Schizophr Res 2003; 60:81-85
42. Yovell Y, Opler LA. Clozapine reverses cocaine craving in a treatment-resistant mentally ill chemical abuser: a case report and a hypothesis. J Nerv Ment Dis 1994;182:591-592
43. Brown E, Nejtek V, Perantie D. Neuroleptics and quetiapine in psychiatric illnesses with comorbid substance abuse. Presented at the annual meeting of the Society of Biological Psychiatry; May 16-18, 2002; Philadelphia, Pa
44. Smelson DA, Losonczy MF, Davis CW, et al. Risperidone decreases craving and relapses in individuals with schizophrenia and cocaine dependence. Can J Psychiatry 2002;47:671-675
45. Conley RR, Kelly DL, Gale EA. Olanzapine response in treatment-refractory schizophrenic patients with a history of substance abuse. Schizophr Res 1998;33:95-101
46. Tsuang J, Marder SR, Han A, et al. Olanzapine treatment for patients with schizophrenia and cocaine abuse. J Clin Psychiatry 2002;63:1180-1181
47. Longo LP. Olanzapine for cocaine craving and relapse prevention in 2 patients. J Clin Psychiatry 2002;63:595-596
48. Littrell KH, Petty RG, Hilligoss NM, et al. Olanzapine treatment for patients with schizophrenia and substance abuse. J Subst Abuse Treat 2001;21:217-221
49. Noordsy DL, O'Keefe C, Mueser KT, et al. Six-month outcomes for patients who switched to olanzapine treatment. Psychiatr Serv 2001;52: 501-507
50. George TP, Sernyak MJ, Ziedonis DM, et al. Effects of clozapine on smoking in chronic schizophrenic outpatients. J Clin Psychiatry 1995; 56:344-346
51. Marcus P, Snyder R. Reduction of comorbid substance abuse with clozapine [letter]. Am J Psychiatry 1995;152:959
52. McEvoy J, Freudenreich O, McGee M, et al. Clozapine decreases smoking in patients with chronic schizophrenia. Biol Psychiatry 1995; 37:550-552
53. George TP, Ziedonis DM, Feingold A, et al. Nicotine transdermal patch and atypical antipsychotic medications for smoking cessation in schizophrenia. Am J Psychiatry 2000;157:1835-1842
54. Buckley P, Thompson P, Way L, et al. Substance abuse among patients with treatment-resistant schizophrenia: characteristics and implications for clozapine therapy. Am J Psychiatry 1994;151:385-389
55. Brown ES, Nejtek VA, Perantie DC, et al. Quetiapine in bipolar disorder and cocaine dependence. Bipolar Disord 2002;4:406-411